Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers in support of ONC010, the company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase inhibitor. The work includes polymer synthesis optimization, characterization methodology development, molecular weight assessment, purification strategy refinement and manufacturing scalability assessments as part of Onco-Innovations' chemistry, manufacturing and controls strategy.
The company said the activities are intended to establish a scalable, reproducible and analytically characterized polymer platform to support future formulation, manufacturing, regulatory and clinical development. Onco-Innovations said Nanosoft's expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform while supporting future GMP manufacturing readiness.
This advancement is significant because it moves ONC010 closer to clinical application. By developing a robust manufacturing process, Onco-Innovations aims to ensure consistent quality and scalability, which are critical for regulatory approvals and eventual commercialization. The partnership with Nanosoft, specialists in polymer science, underscores the company's commitment to leveraging specialized expertise to overcome challenges in nanoparticle drug delivery.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumours. The latest news and updates relating to ONNVF are available in the company's newsroom at https://nnw.fm/ONNVF.
For more information about Onco-Innovations, visit the full press release at https://nnw.fm/BeSoS.
